Introduction
B-cell chronic lymphocytic leukemia (B-CLL) is characterized by a variable clinical course. 1 Somatic mutation of IgV H defines a subgroup with a favorable prognosis, whereas the absence of IgV H mutations is correlated with a worse outcome. [2] [3] [4] [5] [6] [7] [8] [9] Mutations of the 5 0 noncoding region of the BCL-6 gene have also been reported in B-CLL. [10] [11] [12] [13] In two reports, BCL-6 mutations were restricted to B-CLL cases displaying IgV H mutations, supporting the notion that BCL-6 and IgV H mutations are originated by the same mechanism. 11, 12 Conversely, Sahota et al 13 reported subclonal BCL-6 mutations in patients with unmutated IgV H sequences, suggesting that different mechanisms may target the two genes. The clinical significance of the BCL-6 mutation status in B-CLL has not been studied. To address this question, we examined the distribution and clinical relevance of IgV H and BCL-6 mutations in a series of 95 wellcharacterized patients with Binet stage A B-CLL. Our results indicate that, in addition to IgV H mutational status, BCL-6 mutations provide clinically valuable information in early-stage B-CLL.
Study design

Patient samples
Since 1994, over 200 peripheral blood samples from newly diagnosed patients with B-CLL were referred to our institution from different centers throughout the Valencia area. Among them, 95 consecutive untreated patients fulfilling the following criteria were included in the study: (1) diagnosed with Binet stage A B-CLL; (2) had complete clinical, laboratory and followup data; and (3) had available DNA. Clinical and laboratory characteristics of the patients are shown in Table 1 . The median follow-up time of the patients was 28 months (range: 2-96). In all, 22 patients (23%) with progressive disease during follow-up, based on the NCI guidelines, 14 required chemotherapy.
IgV H and BCL-6 mutation analysis
Genomic DNA was prepared as described by Miller et al. 15 
Fluorescent in situ hybridization (FISH) analysis
Clones covering P53 (17p13), ATM (11q22) and D13S19 (13q14) loci, as well as a centromeric chromosome 12 probe, were hybridized in fixed cells obtained from routine cytogenetic analysis, using a reported protocol. 19 All probes were purchased from Vysis.
Statistical analysis
Statistical analysis of the correlation between the groups was explored using Fisher's exact test. Associations between the groups and continuous clinical variables were assessed by the Mann-Whitney test. All P-values less than 0.05 were considered significant. Treatment-free interval (TFI) was calculated from the date of diagnosis to the date of treatment or last follow-up. TFI curves were plotted according to the Kaplan-Meier method, and 
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compared by the log-rank test. Owing to the short median follow-up time, we did not include overall survival in our analysis. The data were analyzed with the SPSS 9.0 software package for Windows.
Results and discussion
Mutations of IgVH were detected in 53 cases (56%), whereas the remaining 42 (44%) were unmutated. The V H 3, V H 4 and V H 1 families were most commonly used in the mutated B-CLL cells (24, 17 and 10 cases, respectively). V H 1-69 gene was used in 12 (29%) of the 42 unmutated cases, an over-representation previously reported in unmutated CLL. 2, 3, 5 The majority of the tumor cells used J H 4 (31 of 95 cases, 33%) or J H 6 (35 of 95 cases, 37%). Owing to of N additions or nucleotide loss, a D segment gene was assigned to sequences in 84 cases. The most commonly used gene was D3 (32 of 84, 38%). Using the multinomial distribution model, 18 evidence for antigen selection was observed in only a minority of cases (13 of 53 mutated cases, 25%), confirming the previous reports. 3, 20, 21 IgV H mutation status defined two subsets of Binet stage A B-CLL with different TFI: CLL cases harboring IgV H mutations had a longer TFI compared to cases with unmutated IgV H genes (TFI not reached vs 44 months, P ¼ 0.0010), in concordance with previous studies. [4] [5] [6] [7] [8] [9] Mutations of BCL-6 were detected in 19 (20%) of 95 Binet stage A B-CLL cases. This prevalence is similar to the BCL-6 mutation prevalence reported in previous studies, 11,12 although our study only included patients at Binet stage A. A total of 33 BCL-6 mutations were detected, all representing single-nucleotide substitutions. In addition, two previously described polymorphims 17 were identified. In agreement with previous reports, BCL-6 mutations were restricted to cases displaying IgV H mutations. 11, 12 Overall, mutational status of BCL-6 as an independent variable did not affect TFI (P ¼ 0.892). However, BCL-6 mutation status could identify clinically distinct subgroups of Binet stage A CLL cases stratified by IgV H mutation status. Based on the occurrence of BCL-6 and IgV H mutations, three genetically distinct subgroups of B-CLL were defined. Group I consisted of cases displaying germline BCL-6 sequences and mutated IgV H genes (34 cases, 36%); group II, characterized by the presence of mutations of BCL-6 and IgV H genes, accounted for 19 cases (20%); and group III included 42 cases (44%) with both genes in germline configuration. TFI was analyzed in these three genetic subgroups (Figure 1) . In all, 38% of the patients with unmutated IgV H (group III) required chemotherapy and had the shortest TFI (median, 44 months; 95% CI, 35-52). Among patients with mutated IgV H , those with unmutated BCL-6 (group I) had stable disease and only one of 34 cases required chemotherapy. On the contrary, patients displaying BCL-6 and IgV H mutations (group II) had progressive disease and 32% required treatment (median TFI, 55 months; 95% CI, 33-76), resembling the clinical course of cases with unmutated IgV H .
To determine whether differences in treatment requirements among the three genetic subgroups reflected differences in other prognostic factors in B-CLL, we analyzed the biological and clinical features of the three subgroups ( Table 1) . As reported previously, 4, 9, 20, 21 CD38 expression was associated with the lack of IgV H mutations: 86% of patients in groups I and II (both carrying IgV H mutations) had CD38 expression o20%, whereas 49% of cases in group III (unmutated IgV H ) had CD38 420% (P ¼ 0.015). We found 28 discordances between the CD38 and the IgV H mutation status. This finding is in agreement with the report of Hamblin et al. 21 In addition, platelet counts were significantly different between patients in group I vs group II (P ¼ 0.038). The most important differences between patients in group I vs those in group II þ group III were CD38 expression and lymphocyte doubling time (P ¼ 0.005 and 0.038, respectively). These data indicate that most known prognostic factors in B-CLL are not different among the groups of patients classified according to the status of IgV H and BCL-6 mutations.
Genomic aberrations detected by FISH analysis, especially deletions of chromosomes 13q, 17p and 11q, and trisomy of chromosome 12, are independent predictors of progression and survival in patients with B-CLL. 22 We wondered whether the distribution of such cytogenetic alterations might differ among the groups of patients defined by mutations of IgV H and BCL-6 genes. Trisomy 12 and deletion of 13q14 were equally distributed among the groups. As expected, deletions of chromosomes 17p13 (P53 locus) and 11q22 (ATM locus) were observed in cases with unmutated IgV H .
7-9 However, we detected one case with loss of P53 that showed mutations of both IgV H and BCL-6 genes. Thus, the presence of poorprognostic cytogenetic alterations can only explain the high risk of progression in minority of cases with mutations of both IgV H and BCL-6 genes.
In summary, our study demonstrates that BCL-6 mutational status adds clinically valuable information to the IgVH mutation status of B-CLL. As the 5 0 noncoding region of BCL-6 contains important regulatory elements, 23 it remains to be determined whether mutations in this region are responsible for a more aggressive disease or consequence of an altered genetic Figure 1 Kaplan-Meier plot of TFI according to the presence of IgV H and BCL-6 mutations. TFI differences in: group I vs group II, Po0.01; Group I vs Group III, Po0.001; Group II vs Group III, P ¼ NS; and Group I vs Groups II þ III, P ¼ 0.0038.
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stability, which in turn may result in deregulation of other genes responsible for B-CLL progression. Future investigations will determine whether BCL-6 mutational status has an impact not only on treatment requirement but also on overall survival.
